Immunome (IMNM) AI Stock Analysis

• Market Cap: $770.92M
• Dividend Yield: N/A
• Average Volume (3M): 1.46M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: -35.50%
• EPS Growth: 3.81%
• Country: US
• Employees: 118
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -5.18
• Shares Outstanding: 87,011,826
• 10 Day Avg. Volume: 1,094,571
• 30 Day Avg. Volume: 1,455,675
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 50.15
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $27.00
• Price Target Upside: 207.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

Immunome's stock score reflects its significant financial hurdles, including negative income and cash flows, which weigh heavily on its performance. Technically, the stock is showing bearish indicators, though some moderate signals suggest potential stabilization. The valuation is unattractive due to negative earnings and no dividend yield. Overall, the stock is facing challenges, with financial performance as the primary concern.

Positive Factors

Financial Health

Cash and cash equivalents were reported at $217 million, which does not include gross proceeds of $172 million from the January 2025 financing.

Market Opportunity

GSIs may represent an estimated $1.8B worldwide market opportunity for desmoid tumors, which are shifting away from surgery and traditional cancer therapies in favor of GSI's.

Pipeline Progress

All pipeline assets remain on track, with the key catalyst, Ph 3 RINGSIDE trial results, expected in 2H25.

Negative Factors

Commercial Uncertainty

Regarding the commercial opportunity, management notes that this will be hard to answer until the profile is known, adding that if data replicates previous results, questions will answer themselves.

Competitive Pressure

The lead asset varegacestat is a Phase 3 oral small molecule gamma-secretase inhibitor with one marketed competitor for rare progressing desmoid tumors, heading into a pivotal topline readout.

Financial Sustainability

As of December 31st 2024, IMNM has $217.3M in cash and investments, excluding likely net proceeds of $161.6M from financing, providing an operating runway into March 2025.

Immunome Business Overview & Revenue Model

Company Description

Immunome, Inc. (IMNM) is a biotechnology company focused on the discovery and development of first-in-class antibody therapeutics designed to harness the human immune system to treat cancer and infectious diseases. Utilizing its proprietary platform, Immunome aims to uncover novel targets and antibodies from the memory B cells of patients who have achieved exceptional immune responses. The company's lead programs are centered around oncology and infectious diseases, with a pipeline that includes potential treatments for various forms of cancer and viral infections.

How the Company Makes Money

Immunome makes money primarily through the development and commercialization of its proprietary antibody-based therapeutics. The company generates revenue through collaborations and partnerships with larger pharmaceutical companies, licensing its technologies, and potentially through future sales of approved therapeutics. Revenue streams may include upfront payments, milestone payments, and royalties from sales if any of its drug candidates successfully reach the market. Immunome's business model relies on advancing its pipeline through clinical trials to achieve regulatory approval and subsequent commercialization, which can attract further investment and partnership opportunities.

Immunome Financial Statement Overview

Summary

Immunome is facing substantial financial challenges, with declining revenue, significant net losses, and negative cash flows. Despite a moderately stable balance sheet with positive equity, the company is heavily reliant on external financing, highlighting the need for improved revenue generation and cost management.

Income Statement

Immunome's income statement reveals a challenging financial situation with declining revenue and significant net losses. The gross profit margin has improved but remains heavily negative due to high operational costs. The net profit margin is also deeply negative, indicating continued financial strain. The company has struggled to grow its revenue, with a notable decline in the past year.

Balance Sheet

The balance sheet shows a moderate level of stability with a positive stockholders' equity. However, the debt-to-equity ratio remains low, reflecting limited leverage, which can be positive but also shows constrained access to debt financing. The equity ratio is relatively strong, indicating that the company is primarily financed by equity rather than debt.

Cash Flow

Immunome's cash flow statement highlights significant challenges, with negative operating and free cash flows indicating ongoing cash burn. The company has relied heavily on financing activities for cash flow, which may not be sustainable in the long term. The free cash flow to net income ratio is negative, underscoring the need for improved operational efficiency.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.04M	14.02M	0.00	0.00	0.00
	Gross Profit
9.04M	-8.91M	-631.00K	-755.00K	-755.00K
	EBIT
-305.80M	-109.53M	-36.90M	-25.20M	-12.26M
	EBITDA
-151.35M	-28.27M	-36.27M	-23.95M	-17.04M
	Net Income Common Stockholders
-292.96M	-106.81M	-37.51M	-24.47M	-17.12M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
217.30M	138.14M	20.32M	49.23M	39.77M
	Total Assets
240.24M	148.54M	24.05M	57.92M	44.52M
	Total Debt
4.83M	1.65M	293.00K	317.00K	613.00K
	Net Debt
-138.52M	-97.03M	-20.03M	-48.91M	-39.15M
	Total Liabilities
59.08M	28.66M	7.39M	9.74M	3.18M
	Stockholders Equity
181.16M	119.88M	16.65M	48.19M	41.34M
Cash Flow		Free Cash Flow
-117.97M	-8.40M	-28.94M	-18.30M	-12.72M
	Operating Cash Flow
-110.79M	-7.57M	-28.69M	-18.23M	-12.13M
	Investing Cash Flow
-85.06M	-30.48M	-248.00K	-79.00K	-586.00K
	Financing Cash Flow
240.53M	116.41M	32.00K	27.77M	49.94M

Immunome Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.79
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Neutral. The current price of 8.79 is above the 20-day moving average (MA) of 7.47, above the 50-day MA of 8.10, and below the 200-day MA of 11.48, indicating a neutral trend. The MACD of 0.28 indicates Negative momentum. The RSI at 63.73 is Neutral, neither overbought nor oversold. The STOCH value of 88.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IMNM.

Immunome Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	56 Neutral	$596.33M	―	-4.99%	―	20.69%	-5.94%
TRVI	55 Neutral	$668.07M	―	-52.59%	―	―	-60.26%
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
IMNM	49 Neutral	$770.92M	―	-194.63%	―	-35.50%	3.81%
PRTA	49 Neutral	$469.37M	―	-23.34%	―	47.92%	17.84%
DNTH	48 Neutral	$697.13M	―	-32.60%	―	351.48%	80.10%
KALV	45 Neutral	$676.13M	―	-150.50%	―	―	-18.75%

Immunome Corporate Events

Immunome CFO Relocation and Compensation Package Unveiled

On January 21, 2025, Immunome, Inc.’s CFO, Max Rosett, accepted a relocation package to move to Bothell, Washington. The package includes a $100,000 cash bonus contingent on his move by January 21, 2026, and employment retention, plus a $300,000 housing bonus tied to purchasing a home and staying with the company for three years, with specific repayment obligations.